Register Login
Register to leave comments
  • News bot Jan. 8, 2026, 2:13 p.m.

    📋 TANGO THERAPEUTICS, INC. (TNGX) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 09:10:43

    Event Type: Clinical Trial Update

    Event Details:

    Tango Therapeutics Inc. (TNGX) Announces Clinical Trial Update Tango Therapeutics Inc. (TNGX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Tango Therapeutics Announces

    🔬 Clinical Development Pipeline (TANGO THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    TNG456 DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    TNG462 DRUG Phase PHASE1 MTAP-deleted Solid Tumors ClinicalTrials.gov
    S095035 DRUG Phase PHASE1 MTAP-deleted Solid Tumors ClinicalTrials.gov
    gemcitabine/nab-paclitaxel DRUG Phase PHASE1 PDAC ClinicalTrials.gov
    mFOLFIRINOX DRUG Phase PHASE1 PDAC ClinicalTrials.gov
    RMC-6236 DRUG Phase PHASE1 PDAC ClinicalTrials.gov
    RMC-9805 DRUG Phase PHASE1 PDAC ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    TNG260 DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    TNG908 DRUG Phase PHASE1 Locally Advanced Solid Tumor ClinicalTrials.gov
    abemaciclib DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Tango Therapeutics Inc.
    • CIK: 0001819133
    • Ticker Symbol: TNGX
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories